Natera shared a post on X:
“Join Michael Adashek, medical oncologist, hematologist, and director of GU medical oncology at chesapeake urology, for a live, case-based webinar designed for urologists.
This session will explore how ctDNA testing may provide additional insight across key MIBC decision points, including:
- After TURBT and before cystectomy
- During neoadjuvant therapy
- After cystectomy and throughout surveillance.
Dr. Adashek will review practical patient cases and discuss relevant clinical data, including IMvigor011 and NIAGARA, to help illustrate how ctDNA may support multidisciplinary MIBC management.”
Other articles about Natera on OncoDaily.